Annual report
4578.TEDINET S100QJ0T
Period2022-01-01 → 2022-12-31
Filed2023-03-31
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.74T | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥1.50T | 2021-01-01 → 2021-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥1.42T | 2020-01-01 → 2020-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.40T | 2019-01-01 → 2019-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.29T | 2018-01-01 → 2018-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥150.3bn | 2022-01-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥154.5bn | 2021-01-01 → 2021-12-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥173.0bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥163.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥190.0bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥173.5bn | 2019-01-01 → 2019-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥109.5bn | 2018-01-01 → 2018-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥134.0bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥125.5bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥148.1bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥127.2bn | 2019-01-01 → 2019-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥82.5bn | 2018-01-01 → 2018-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥137.4bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥129.2bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥3.10T | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.82T | at 2021-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.63T | at 2020-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.58T | at 2019-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.48T | at 2018-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥840.2bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥775.7bn | at 2021-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.26T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.05T | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.88T | at 2020-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥2.23T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.01T | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.85T | at 2020-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.77T | at 2019-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.70T | at 2018-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥471.6bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥410.7bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥356.9bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥334.0bn | at 2019-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥285.0bn | at 2018-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥211.8bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥228.9bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥232.8bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥192.6bn | 2019-01-01 → 2019-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥135.8bn | 2018-01-01 → 2018-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥81.6bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥95.3bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥99.9bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥52.3bn | 2019-01-01 → 2019-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥93.3bn | 2018-01-01 → 2018-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥95.5bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥95.8bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥104.9bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥89.3bn | 2019-01-01 → 2019-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥89.2bn | 2018-01-01 → 2018-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥247.01 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥231.32 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥273.15 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥234.55 | 2019-01-01 → 2019-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥152.24 | 2018-01-01 → 2018-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥246.99 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥231.15 | 2021-01-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥272.35 | 2020-01-01 → 2020-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥231.13 | 2019-01-01 → 2019-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥151.26 | 2018-01-01 → 2018-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥4,101.12 | at 2022-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,707.64 | at 2021-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,415.54 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,257.17 | at 2019-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,145.71 | at 2018-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.3% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.5% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.4% | at 2019-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.8% | at 2018-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 6.3% | 2022-01-01 → 2022-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.5% | 2021-01-01 → 2021-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.2% | 2020-01-01 → 2020-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.3% | 2019-01-01 → 2019-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 4.7% | 2018-01-01 → 2018-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 33,482 | at 2022-12-31 | Cons. | Number of employees |
| Employees | 33,226 | at 2021-12-31 | Cons. | Number of employees |
| Employees | 33,151 | at 2020-12-31d | Cons. | Number of employees |
| Employees | 32,992 | at 2019-12-31d | Cons. | Number of employees |
| Employees | 32,935 | at 2018-12-31d | Cons. | Number of employees |
| Revenue | ¥57.0bn | 2022-01-01 → 2022-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥115.0bn | 2021-01-01 → 2021-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥102.7bn | 2020-01-01 → 2020-12-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥66.2bn | 2019-01-01 → 2019-12-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥86.1bn | 2018-01-01 → 2018-12-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥44.3bn | 2022-01-01 → 2022-12-31 | Standalone | Operating income |
| Operating income | ¥103.4bn | 2021-01-01 → 2021-12-31 | Standalone | Operating income |
| Ordinary income | ¥46.4bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥104.8bn | 2021-01-01 → 2021-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥93.5bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥57.8bn | 2019-01-01 → 2019-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥79.6bn | 2018-01-01 → 2018-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥46.0bn | 2022-01-01 → 2022-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥104.8bn | 2021-01-01 → 2021-12-31 | Standalone | Income before income taxes |
| Net income | ¥47.4bn | 2022-01-01 → 2022-12-31 | Standalone | Profit loss |
| Net income | ¥106.0bn | 2021-01-01 → 2021-12-31 | Standalone | Profit loss |
| Net income | ¥94.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥58.4bn | 2019-01-01 → 2019-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥80.0bn | 2018-01-01 → 2018-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.27T | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥1.25T | at 2021-12-31 | Standalone | Assets |
| Total assets | ¥1.21T | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.16T | at 2019-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.05T | at 2018-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥208.2bn | at 2022-12-31 | Standalone | Liabilities |
| Total liabilities | ¥179.3bn | at 2021-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.06T | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.07T | at 2021-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.02T | at 2020-12-31d | Standalone | Net assets |
| Net assets / equity | ¥977.1bn | at 2019-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥970.8bn | at 2018-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥129.1bn | at 2022-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥44.8bn | at 2021-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥87.37 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.5 | 2021-01-01 → 2021-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥174.03 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥107.68 | 2019-01-01 → 2019-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.7 | 2018-01-01 → 2018-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥87.37 | 2022-01-01 → 2022-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥195.5 | 2021-01-01 → 2021-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.03 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥107.67 | 2019-01-01 → 2019-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥147.67 | 2018-01-01 → 2018-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥100 | 2022-01-01 → 2022-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2021-01-01 → 2021-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2020-01-01 → 2020-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2019-01-01 → 2019-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2018-01-01 → 2018-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,959.51 | at 2022-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,970.44 | at 2021-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,875.15 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,801.86 | at 2019-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,791.66 | at 2018-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 83.6% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.6% | at 2021-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.2% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.4% | at 2019-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.6% | at 2018-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.4% | 2022-01-01 → 2022-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2021-01-01 → 2021-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.5% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2019-01-01 → 2019-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2018-01-01 → 2018-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 557,835,617 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2021-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2019-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2018-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 147 | at 2022-12-31 | Standalone | Number of employees |
| Employees | 137 | at 2021-12-31 | Standalone | Number of employees |
| Employees | 111 | at 2020-12-31d | Standalone | Number of employees |
| Employees | 104 | at 2019-12-31d | Standalone | Number of employees |
| Employees | 94 | at 2018-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 61
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-01-01 → 2022-12-31 | ¥10.7bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-12-31 | −¥42.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-12-31 | −¥42.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-12-31 | −¥47.9bn |
| Consumer Productsreportable segment | capex | 2022-01-01 → 2022-12-31 | ¥3.3bn |
| Consumer Productsreportable segment | employees | at 2022-12-31 | 651 pure |
| Consumer Productsreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥35.9bn |
| Consumer Productsreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥35.9bn |
| Consumer Productsreportable segment | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥26m |
| Consumer Productsreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥6.9bn |
| Nutraceuticalsreportable segment | capex | 2022-01-01 → 2022-12-31 | ¥15.0bn |
| Nutraceuticalsreportable segment | employees | at 2022-12-31 | 8227 pure |
| Nutraceuticalsreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥437.0bn |
| Nutraceuticalsreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥437.0bn |
| Nutraceuticalsreportable segment | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥32m |
| Nutraceuticalsreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥56.3bn |
| Otherreportable segment | capex | 2022-01-01 → 2022-12-31 | ¥9.3bn |
| Otherreportable segment | employees | at 2022-12-31 | 3519 pure |
| Otherreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥169.2bn |
| Otherreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥127.3bn |
| Otherreportable segment | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥42.0bn |
| Otherreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥11.9bn |
| Pharmaceuticalsreportable segment | capex | 2022-01-01 → 2022-12-31 | ¥101.0bn |
| Pharmaceuticalsreportable segment | employees | at 2022-12-31 | 19639 pure |
| Pharmaceuticalsreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥1.14T |
| Pharmaceuticalsreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥1.14T |
| Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥123.1bn |
| —segment total | capex | 2022-01-01 → 2022-12-31 | ¥128.6bn |
| —segment total | employees | at 2022-12-31 | 32036 pure |
| —segment total | revenue | 2022-01-01 → 2022-12-31 | ¥1.78T |
| —segment total | revenue external | 2022-01-01 → 2022-12-31 | ¥1.74T |
| —segment total | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥42.0bn |
| —segment total | segment profit | 2022-01-01 → 2022-12-31 | ¥198.3bn |
| Reconciling Itemsreconciling | capex | 2021-01-01 → 2021-12-31 | ¥17.5bn |
| Reconciling Itemsreconciling | revenue | 2021-01-01 → 2021-12-31 | −¥37.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-01-01 → 2021-12-31 | −¥37.8bn |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-12-31 | −¥46.2bn |
| Consumer Productsreportable segment | capex | 2021-01-01 → 2021-12-31 | ¥2.7bn |
| Consumer Productsreportable segment | revenue | 2021-01-01 → 2021-12-31 | ¥31.9bn |
| Consumer Productsreportable segment | revenue external | 2021-01-01 → 2021-12-31 | ¥31.9bn |
| Consumer Productsreportable segment | revenue intersegment | 2021-01-01 → 2021-12-31 | ¥25m |
| Consumer Productsreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥5.3bn |
| Nutraceuticalsreportable segment | capex | 2021-01-01 → 2021-12-31 | ¥19.6bn |
| Nutraceuticalsreportable segment | revenue | 2021-01-01 → 2021-12-31 | ¥376.6bn |
| Nutraceuticalsreportable segment | revenue external | 2021-01-01 → 2021-12-31 | ¥376.6bn |
| Nutraceuticalsreportable segment | revenue intersegment | 2021-01-01 → 2021-12-31 | ¥50m |
| Nutraceuticalsreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥46.6bn |
| Otherreportable segment | capex | 2021-01-01 → 2021-12-31 | ¥10.7bn |
| Otherreportable segment | revenue | 2021-01-01 → 2021-12-31 | ¥150.0bn |
| Otherreportable segment | revenue external | 2021-01-01 → 2021-12-31 | ¥112.3bn |
| Otherreportable segment | revenue intersegment | 2021-01-01 → 2021-12-31 | ¥37.7bn |
| Otherreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥11.4bn |
| Pharmaceuticalsreportable segment | capex | 2021-01-01 → 2021-12-31 | ¥93.6bn |
| Pharmaceuticalsreportable segment | revenue | 2021-01-01 → 2021-12-31 | ¥977.5bn |
| Pharmaceuticalsreportable segment | revenue external | 2021-01-01 → 2021-12-31 | ¥977.5bn |
| Pharmaceuticalsreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥137.3bn |
| —segment total | capex | 2021-01-01 → 2021-12-31 | ¥126.6bn |
| —segment total | revenue | 2021-01-01 → 2021-12-31 | ¥1.54T |
| —segment total | revenue external | 2021-01-01 → 2021-12-31 | ¥1.50T |
| —segment total | revenue intersegment | 2021-01-01 → 2021-12-31 | ¥37.8bn |
| —segment total | segment profit | 2021-01-01 → 2021-12-31 | ¥200.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,275
| Item | Context | Value | Unit |
|---|---|---|---|
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row52Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row53Member | Original text (Japanese)武田薬品工業㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row53Member | Original text (Japanese)医療関連事業セグメントにおける情報収集のため、保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row53Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row54Member | Original text (Japanese)科研製薬㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row54Member | Original text (Japanese)医療関連事業セグメントにおける情報収集のため、保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row54Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row55Member | Original text (Japanese)テルモ㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row55Member | Original text (Japanese)医療関連事業セグメントにおける情報収集のため、保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row55Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row56Member | Original text (Japanese)持田製薬㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row56Member | Original text (Japanese)医療関連事業セグメントにおける情報収集のため、保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row56Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row57Member | Original text (Japanese)ロート製薬㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row57Member | Original text (Japanese)医療関連事業セグメントにおける情報収集のため、保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row57Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row58Member | Original text (Japanese)ゼリア新薬工業㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row58Member | Original text (Japanese)医療関連事業セグメントにおける情報収集のため、保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row58Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row59Member | Original text (Japanese)アステラス製薬㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row59Member | Original text (Japanese)医療関連事業セグメントにおける情報収集のため、保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row59Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row60Member | Original text (Japanese)扶桑薬品工業㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row60Member | Original text (Japanese)医療関連事業セグメントにおける情報収集のため、保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row60Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row61Member | Original text (Japanese)㈱ビー・エム・エル | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row61Member | Original text (Japanese)定期的に個別銘柄について検討した結果、売却しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row61Member | － | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row62Member | SomaLogic. Inc. | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row62Member | Original text (Japanese)定期的に個別銘柄について検討した結果、売却しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row62Member | － | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row63Member | Original text (Japanese)㈱リボミック | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row63Member | Original text (Japanese)定期的に個別銘柄について検討した結果、売却しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row63Member | － | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row64Member | Original text (Japanese)㈱ポプラ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row64Member | Original text (Japanese)定期的に個別銘柄について検討した結果、売却しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row64Member | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment second largest holding company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment second largest holding company | CurrentYearDuration | Original text (Japanese)追加取得（７銘柄）新規取得（４銘柄） | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Arcus Biosciences, Inc. | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row2Member | Werewolf Therapeutics, Inc. | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row2Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row3Member | ORIC Pharmaceuticals, Inc. | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row3Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row4Member | NextCure, Inc. | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row4Member | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |